The pediatric AIDS severity score (PASS): A multidimensional AIDS-severity adjustment for pediatric HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 5, 2006, Pages 603-610

  Seage III, George R ^a,b   Buchacz, Kate ^b   Weinberg, Geoffrey A ^c   Patel, Kunjal ^a,b   McIntosh, Kenneth ^d   Dankner, Wayne M ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical outcomes; Confounding by severity; Disease progression; Pediatric AIDS; Severity adjustment; Survival

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BODY MASS; CLINICAL FEATURE; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; IMMUNITY; INFANT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEDIATRIC AIDS SEVERITY SCORE; PERINATAL INFECTION; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RATING SCALE; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; UNITED STATES; VALIDATION PROCESS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; SEVERITY OF ILLNESS INDEX;

EID: 33845368540     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000242453.20521.4f     Document Type: Article

References (53)

1. Gortmaker SL, Hughes M, Cervia J, et al, for the Pediatric AIDS Clinical Trials Group Protocol 219. The impact of protease inhibitor combination therapy on mortality among children and youth infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
2. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS registry. JAMA. 2000;284:190-197.
3. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000;283:492-498.
4. Walker AM. Confounding by indication. Epidemiology. 1996;7:335-336.
5. Ahdieh L, Gange SJ, Greenblatt R, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol. 2000;152:923-933.
6. Aschengrau A, Seage GR III. Essentials of Epidemiology in Public Health Research. Boston, MA: Jones and Bartlett; 2003:286-287.
7. Rothenberg R,Woelfel M, Stoneburner R, et al. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. N Engl J Med. 1987;317:1297-1302.
8. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA. 1990;263:402-406.
9. Moore RD, Hidalgo J, Sugland BW, et al. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:1412-1416.
10. Seage GR, Oddleifson S, Carr E, et al. Survival with AIDS in Massachusetts, 1979 to 1989. Am J Public Health. 1993;83:72-78.
11. Justice AC, Feinstein AR,Wells CK. A new prognostic staging system for the acquired immunodeficiency syndrome. N Engl J Med. 1989;21:1388-1393.
12. Turner BJ, Markson LE, McKee L, et al. The AIDS-defining diagnosis and subsequent complications: a survival-based severity index. J Acquir Immune Defic Syndr. 1991;4:1059-1071.
13. Seage GR, Gatsonis C, Weissman J, et al. The Boston Health Study Staging System: a multidimensional approach to predicting AIDS survival. Am J Public Health. 1997;87:567-573.
14. El-Sadr W, Neaton JD. Annotation: wanted - a simple and meaningful HIV staging system. Am J Public Health. 1997;87:546-547.
15. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep. 1998;47:1-38.
16. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4 T lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761.
17. Scott GB, Hutto C, Makuch R, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med. 1989;321:1791-1796.
18. Diaz C, Hanson C, Cooper ER, et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:221-228.
19. Mofenson LM, Harris DR, Rich K, et al. Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. AIDS. 1999;13:31-39.
20. Carey VJ, Yong FH, Frenkel LM, et al. Pediatric AIDS prognosis using somatic growth velocity. AIDS. 1998;12:1361-1369.
21. McKinney RE, Wilfert C, and the AIDS Clinical Trials Group Protocol 043 Study Group. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. J Pediatr. 1994;125:728-733.
22. Pearson DA, McGrath NM, Nozyce M, et al. Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatrics. 2000;106:e76.
23. Gaughan DM, Hughes MD, Seage GR III, et al, for the PACTG 219 Team. The prevalence of pain in pediatric HIV/AIDS as reported by participants in the Pediatric Late Outcomes Study (PACTG 219). Pediatrics. 2002;109:1144-1152.
24. Lindsey JC, Hughes MD, McKinney RE, et al. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline and survival in HIV-infected children. J Infect Dis. 2000;182:1385-1393.
25. Gortmaker SL, Lenderking WR, Clark C, et al, and the ACTG 219 Team. Development and use of a pediatric quality of life questionnaire in AIDS clinical trials: reliability and validity of the general health assessment for children. In: Drotar D, ed., Assessing Pediatric Health-Related Quality of Life and Functional Status: Implications for Research and Practice. Mahwah, NJ: Lawrence Erlbaum Associates, Inc.; 1998:219-235.
26. Bayley N. Bayley Scales of Infant Development. San Antonio, TX: The Psychological Corporation; 1969.
27. Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: The Psychological Corporation; 1993.
28. McCarthy D. McCarthy Scales of Children's Ability. Cleveland, OH: The Psychological Corporation; 1970.
29. Wechsler D. Wechsler Preschool and Primary Scale of Intelligence. Revised. San Antonio, TX: The Psychological Corporation; 1989.
30. Wechsler D. Wechsler Intelligence Scale for Children. 3rd ed. San Antonio, TX: The Psychological Corporation; 1991.
31. Wechsler D. Wechsler Intelligence Scale for Children. Revised. San Antonio, TX: The Psychological Corporation; 1974.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
33. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley and Sons; 1980:22-23, 79-81.
34. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43:1-19.
35. Harrell FE, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;2:143-152.
36. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
37. Galli L, de Martino M, Tovo P-A, et al. Predictive value of the HIV paediatric classification system for the long-term course of perinatally infected children. Int J Epidemiol. 2000;29:573-578.
38. Kalish LA, McIntosh K, Read JS, et al. Evaluation of human immunodeficiency virus (HIV) type I viral load, CD4 T cell level, and clinical class as time-fixed and time-varying makers of disease progression in HIV-1-infected children. J Infect Dis. 1999;180:1514-1520.
39. Pizzo PA, Eddy J, Fallon J, et al. Effect of continuous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988;319:889-896.
40. Tepper VJ, Farley JJ, Rothman MI, et al. Neurodevelopmental/ neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir. Pediatrics. 1998;101:462-463.
41. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr. 1998;132:543-546.
42. Gavin P, Yogev R. Central nervous system abnormalities in pediatric human immunodeficiency virus infection. Pediatr Neurosurg. 1999;31:115-123.
43. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurological diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology. 1994;44:1892-1900.
44. Johann-Liang R, Cervia JS, Noel GJ. Characteristics of human immunodeficiency virus-infected children at the time of death: an experience in the 1990s. Pediatr Infect Dis J. 1997;16:1145-1150.
45. Mofenson LM, Harris DR, Moye J, et al. for the NICHD IVIG Clinical Trial Study Group. Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1 infected children in resource-poor settings. Lancet. 2003;362:1625-1627.
46. Crowe S, Turnbull S, Oelrichs R, et al. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis. 2003;37(Suppl 1):S25-S35.
47. Patel K, Weinberg GA, Buchacz K, et al. for the PACTG 219 Study Team. Simple Pediatric AIDS Severity Score (PASS): a pediatric severity score for resource-poor settings. J. Acquir Immune Defic Syndr. 2006;43:611-617.
48. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149:981-983.
49. Robins JM. The analysis of randomized and non-randomized AIDS treatment trials using a new approach to causal interference in longitudinal studies. In: Sechrest L, Freeman H, Mulley A, eds. Health Service Research Methodology: A Focus on AIDS. Rockville, MD: National Center for Health Services Research, U.S. Public Health Service; 1989;113-159.
50. Robins JM, Blevins D, Ritter G, et al. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia (PCP) on the survival of AIDS patients. Epidemiology. 1992;3:319-336; Erratum in Epidemiology 1993;4:189.
51. Robins JM, Hernán M, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
52. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structured models. Am J Epidemiol. 2003;158:687-694.
53. Dunn D, For the Paediatric Prognostic Markers Collaborative Study. Predictive Value of absolute CD4 cell count for disease progression in ontreated HIV-1-infected children. AIDS. 2006;20:1289-1294.